Bigul

Fabino Life Sciences Ltd - 543444 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayFabino Life Sciences Ltd 2CINU24100DL2011PLC226781 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.05 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: JEEL POSHIYA Designation: COMPANY SECRETARY EmailId: info@fabinolife.com Name of the Chief Financial Officer: PANKAJ JAIN Designation: CFO EmailId: info@fabinolife.com Date: 30/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
30-04-2022
Bigul

Fabino Life Sciences Ltd - 543444 - Certificate As Per Regulation 7(3) SEBI (Listing Obligation And Disclosures Requirements) Regulations, 2015 For Year Ended March 31, 2022

Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby certify that all activities in relation to both physical and electronic share transfer facility are maintained during the period from April 01, 2021 to March 31, 2022 (both days inclusive) by company's Share Transfer Agent ie. Bigshare Services Private Limited having permanent SEBI Registration No: INRO00001385. Kindly take note of the above.
20-04-2022
Bigul

Fabino Life Sciences Ltd - 543444 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Dear Sir, Please find enclosed herewith the Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2022 dated April 07, 2022 received from M/s Bigshare Services Private Limited, the Registrar and Share Transfer Agent of the Company. Kindly acknowledge the receipt.
18-04-2022
Bigul

Fabino Life Sciences Ltd - 543444 - Certificate As Per Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Year Ended March 31, 2022

Dear Sir/Madam, Please find enclosed herewith the certificate dated April 16, 2022 from Spanj & Associates, Practicing Company Secretaries under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the year ended March 31, 2022. This is for your information and records.
18-04-2022
Bigul

Fabino Life Sciences Ltd - 543444 - Statement Of Investor Complaints For The Quarter Ended March 2022

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Jeel PoshiyaDesignation :- Company Secretary and Compliance Officer
18-04-2022
Bigul

Fabino Life Sciences Ltd - 543444 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aryaman Capital Markets Ltd
30-03-2022
Bigul

Fabino Life Sciences Ltd - 543444 - Closure of Trading Window

Dear Sir/Madam, We hereby inform you that in terms of Company's Code for prevention of Insider Trading framed under SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company would remain close from Friday, 1st April, 2022 till the completion of 48 hours after announcement of the Audited Financial Results of the Quarter and year ended 31st March, 2022; for Designated persons of the Company including their immediate relatives. The date of Board meeting to be held for the consideration and approval of the Financial Results of the above mentioned period will be communicated in due course of time. Kindly take the same on your record.
30-03-2022
Bigul

Fabino Life Sciences Ltd - 543444 - Statement Of Investor Complaints For The Quarter Ended December 2021

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Jeel PoshiyaDesignation :- Company Secretary and Compliance Officer
19-01-2022
Bigul

Fabino Life Sciences Ltd - 543444 - Listing of equity shares of Fabino Life Sciences Ltd

Trading Members of the Exchange are hereby informed that effective from January 13, 2022 the equity shares of Fabino Life Sciences Ltd (Scrip Code: 543444) are listed and admitted to dealings on the Exchange in the list of ''MT'' Group Securities. For further details please refer to the notice no 20220112-10 dated January 12, 2022.
13-01-2022
Close

Let's Open Free Demat Account